Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma

Bone Marrow Transplantation

Volumn 36, Issue 11, 2005, Pages 963-969

  Gerull, S ^a   Goerner, M ^a   Benner, A ^b   Hegenbart, U ^a   Klein, U ^a   Schaefer, H ^a   Goldschmidt, H ^a   Ho, Anthony Dick ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Allogeneic transplantation; Graft versus host disease; Multiple myeloma; Nonmyeloablative transplantation

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THALIDOMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 28544446473     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705161     Document Type: Article

References (44)

1. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
2. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
3. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
5. Tosi P, Ronconi S, Zamagni E et al. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation. Haematologica 2001; 86: 409-413.
6. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000; 39: 843-847.
7. Moehler T, Neben K, Benner A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846-3848.
8. Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-172.
9. Turesson I, Abildgaard N, Ahlgren T et al. Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors. Br J Haematol 1999; 106: 1005-1012.
10. Zojer N, Konigsberg R, Ackermann J et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925-1930.
11. 2-microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy. Blood 2001; 97: 1566-1571.
12. Shaughnessy Jr J, Tian E, Sawyer J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haemtol 2003; 120: 44-52.
13. Durie BG, Kyle RA, Belch A et al. Myeloma management guidelines: A common report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379-398.
14. Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38: 243-249.
15. Tricot G, Vesole D, Jagannath S et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
16. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft versus myeloma effect. Leukemia 1997; 11: 281-283.
17. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
18. Bjorkstrand B, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation vs autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
19. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.
20. Gharton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1322.
21. Nagler A, Or R, Naparstek E et al. Second allogeneic transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Exp Hematol 2000; 28: 1096-1104.
22. Khouri IF, Keating M, Korbling M et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
23. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
24. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's disease. J Clin Oncol 2000; 18: 3918-3924.
25. Mohty M, Fegueux N, Exbrayat C et al. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies. Bone Marrow Transplant 2001; 28: 335-339.
26. Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001, 375-391.
27. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor leukocyte infusions. Blood 2001; 97: 2574-2579.
28. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.
29. Maloney DG, Molina AJ, Sahebi F et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
30. Mohty M, Boiron JM, Damaj G et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 77-84.
31. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295-304.
32. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
33. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
34. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986; 5: 255-260.
35. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 47: 457-481.
36. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Ann Statist 1982; 10: 1100-1120.
37. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2004 (ISBN 3-900051-00-3).
38. Kroger N, Einsele H, Wolff D et al. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant 2003; 31: 973-979.
39. Kroger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
40. Giralt S, Aleman A, Anagnostopoulos A et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373.
41. Einsele H, Schaefer HJ, Hebart H et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411-418.
42. Luft T, Moos M, Goldschmidt H et al. Dissociation of putative graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646-653.
43. Perez-Simon JA, Martino R, Alegre A et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104-108.
44. Kroger N, Perez-Simon J, Myint H et al. Influence of timing allogeneic stem cell transplantation after dose-reduced melphalan/fludarabine conditioning in multiple myeloma. Blood 2003; 102: 728a (abstr. 2694).